Cannabis Testing Services Market
Description
Cannabis Testing Services Market Summary
The global cannabis testing services market size was estimated at USD 2.42 billion in 2025 and is projected to reach USD 7.19 billion by 2033, growing at a CAGR of 14.36% from 2026 to 2033. Factors such as increasing legalization of cannabis for recreational and medical purposes, rising use of cannabis in medicinal applications, the launch of technologically advanced instruments for cannabis testing, and growing focus on ensuring product quality and safety boost the market growth.
For instance, in April 2024, Germany legalized cannabis for recreational purposes. Under this law, adults in Germany possess 25 grams of marijuana for recreational purposes. Several states and countries are establishing standardized testing and certification programs, which are anticipated to propel the cannabis testing services industry’s growth. These programs are designed to assure quality and regulate product safety and are thus expected to further boost market growth. For instance, in January 2024, Minnesota State Community and Technical College (M State) collaborated with Green Flower, a cannabis education and training center, to offer three new certificate programs for students seeking careers in the cannabis industry. In addition, in April 2023, ACT Laboratories and SC Labs collaborated and launched Trust in Testing Certification, a new set of national standards for cannabis testing.
The growing legalization of cannabis across the globe for medical and recreational purposes fuels the market growth. By opening new markets and increasing consumer access, this trend has a positive impact on the growth trajectory. As of June 2025, forty U.S. states, three territories, and the District of Columbia have legalized cannabis for medical use, while twenty-four states, three territories, and the District of Columbia allow adult recreational use. Several states also permit the use of low-THC, high-CBD products under limited medical programs, providing patients access to cannabidiol-rich formulations with minimal psychoactive effects.
Various countries across Asia and Europe are set to legalize medical cannabis for the growing patient population. This number is anticipated to rise significantly over the forecast period. Due to this increasing patient population, setting up effective testing services becomes essential. For instance, the following table represents the number of medical cannabis patients in the U.S.
Global Cannabis Testing Services Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research, Inc. has segmented the cannabis testing services market report based on service, end use, and region:
The global cannabis testing services market size was estimated at USD 2.42 billion in 2025 and is projected to reach USD 7.19 billion by 2033, growing at a CAGR of 14.36% from 2026 to 2033. Factors such as increasing legalization of cannabis for recreational and medical purposes, rising use of cannabis in medicinal applications, the launch of technologically advanced instruments for cannabis testing, and growing focus on ensuring product quality and safety boost the market growth.
For instance, in April 2024, Germany legalized cannabis for recreational purposes. Under this law, adults in Germany possess 25 grams of marijuana for recreational purposes. Several states and countries are establishing standardized testing and certification programs, which are anticipated to propel the cannabis testing services industry’s growth. These programs are designed to assure quality and regulate product safety and are thus expected to further boost market growth. For instance, in January 2024, Minnesota State Community and Technical College (M State) collaborated with Green Flower, a cannabis education and training center, to offer three new certificate programs for students seeking careers in the cannabis industry. In addition, in April 2023, ACT Laboratories and SC Labs collaborated and launched Trust in Testing Certification, a new set of national standards for cannabis testing.
The growing legalization of cannabis across the globe for medical and recreational purposes fuels the market growth. By opening new markets and increasing consumer access, this trend has a positive impact on the growth trajectory. As of June 2025, forty U.S. states, three territories, and the District of Columbia have legalized cannabis for medical use, while twenty-four states, three territories, and the District of Columbia allow adult recreational use. Several states also permit the use of low-THC, high-CBD products under limited medical programs, providing patients access to cannabidiol-rich formulations with minimal psychoactive effects.
Various countries across Asia and Europe are set to legalize medical cannabis for the growing patient population. This number is anticipated to rise significantly over the forecast period. Due to this increasing patient population, setting up effective testing services becomes essential. For instance, the following table represents the number of medical cannabis patients in the U.S.
Global Cannabis Testing Services Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research, Inc. has segmented the cannabis testing services market report based on service, end use, and region:
- Service Outlook (Revenue, USD Million, 2021 - 2033)
- Potency Testing
- Terpene Profiling
- Heavy Metal Testing
- Pesticide Screening
- Microscopy Testing
- Residual Solvent Screening
- Others
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Cannabis Cultivators/Growers
- Cannabis Drug Manufacturers
- Others (Research Institutes & Labs)
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- Poland
- Czech Republic
- Switzerland
- Croatia
- Netherlands
- Spain
- Asia Pacific
- China
- Japan
- India
- Thailand
- Australia
- New Zealand
- Latin America and Caribbean
- Brazil
- Uruguay
- Colombia
- Africa
Table of Contents
150 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Drug Class
- 1.2.2. Indication
- 1.2.3. End Use
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR’s Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. Biosimilars Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter’s Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- Chapter 4. Biosimilars Market: Drug Class Business Analysis
- 4.1. Drug Class Market Share, 2025 & 2033
- 4.2. Drug Class Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Billion)
- 4.4. Monoclonal Antibodies (mAbs)
- 4.4.1. Monoclonal Antibodies (mAbs) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 4.5. Growth Factors & Hematopoietic Agents
- 4.5.1. Growth Factors & Hematopoietic Agents Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 4.6. Insulin & Analogues
- 4.6.1. Insulin & Analogues Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 4.7. Osteoporosis / Bone Metabolism Agents
- 4.7.1. Osteoporosis / Bone Metabolism Agents Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 4.8. Others
- 4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- Chapter 5. Biosimilars Market: Indication Business Analysis
- 5.1. Indication Market Share, 2025 & 2033
- 5.2. Indication Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Billion)
- 5.4. Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis)
- 5.4.1. Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 5.5. Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric)
- 5.5.1. Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 5.6. Diabetes Mellitus (Type 1 & Type 2)
- 5.6.1. Diabetes Mellitus (Type 1 & Type 2) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 5.7. Ophthalmic Disorders (Wet AMD, DME, RVO)
- 5.7.1. Ophthalmic Disorders (Wet AMD, DME, RVO) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 5.8. Hematologic / Rare Blood Disorders
- 5.8.1. Hematologic / Rare Blood Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 5.9. Others
- 5.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- Chapter 6. Biosimilars Market: End Use Business Analysis
- 6.1. End Use Market Share, 2025 & 2033
- 6.2. End Use Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Billion)
- 6.4. Hospitals
- 6.4.1. Hospitals Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 6.5. Specialty Pharmacies
- 6.5.1. Specialty Pharmacies Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 6.6. Online & Retail Channels
- 6.6.1. Online & Retail Channels Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- Chapter 7. Biosimilars Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2025 & 2033
- 7.2. Regional Market Dashboard
- 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 7.4. North America
- 7.4.1. North America Biosimilars Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Type Disease Prevalence
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. Reimbursement Framework
- 7.4.2.5. U.S. Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Type Disease Prevalence
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. Reimbursement Framework
- 7.4.3.5. Canada Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Type Disease Prevalence
- 7.4.4.3. Regulatory Framework
- 7.4.4.4. Reimbursement Framework
- 7.4.4.5. Mexico Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5. Europe
- 7.5.1. Europe Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Type Disease Prevalence
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. Reimbursement Framework
- 7.5.2.5. UK Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Type Disease Prevalence
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. Reimbursement Framework
- 7.5.3.5. Germany Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Type Disease Prevalence
- 7.5.4.3. Regulatory Framework
- 7.5.4.4. Reimbursement Framework
- 7.5.4.5. France Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Type Disease Prevalence
- 7.5.5.3. Regulatory Framework
- 7.5.5.4. Reimbursement Framework
- 7.5.5.5. Italy Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Type Disease Prevalence
- 7.5.6.3. Regulatory Framework
- 7.5.6.4. Reimbursement Framework
- 7.5.6.5. Spain Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.7. Denmark
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Type Disease Prevalence
- 7.5.7.3. Regulatory Framework
- 7.5.7.4. Reimbursement Framework
- 7.5.7.5. Denmark Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.8. Sweden
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Type Disease Prevalence
- 7.5.8.3. Regulatory Framework
- 7.5.8.4. Reimbursement Framework
- 7.5.8.5. Sweden Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.9. Norway
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Type Disease Prevalence
- 7.5.9.3. Regulatory Framework
- 7.5.9.4. Reimbursement Framework
- 7.5.9.5. Norway Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Type Disease Prevalence
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. Reimbursement Framework
- 7.6.2.5. Japan Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Type Disease Prevalence
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. Reimbursement Framework
- 7.6.3.5. China Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Type Disease Prevalence
- 7.6.4.3. Regulatory Framework
- 7.6.4.4. Reimbursement Framework
- 7.6.4.5. India Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.5. Australia
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Type Disease Prevalence
- 7.6.5.3. Regulatory Framework
- 7.6.5.4. Reimbursement Framework
- 7.6.5.5. Australia Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.6. South Korea
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Type Disease Prevalence
- 7.6.6.3. Regulatory Framework
- 7.6.6.4. Reimbursement Framework
- 7.6.6.5. South Korea Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.7. Thailand
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Type Disease Prevalence
- 7.6.7.3. Regulatory Framework
- 7.6.7.4. Reimbursement Framework
- 7.6.7.5. Thailand Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.7. Latin America
- 7.7.1. Latin America Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Type Disease Prevalence
- 7.7.2.3. Regulatory Framework
- 7.7.2.4. Reimbursement Framework
- 7.7.2.5. Brazil Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Type Disease Prevalence
- 7.7.3.3. Regulatory Framework
- 7.7.3.4. Reimbursement Framework
- 7.7.3.5. Argentina Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Type Disease Prevalence
- 7.8.2.3. Regulatory Framework
- 7.8.2.4. Reimbursement Framework
- 7.8.2.5. South Africa Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Type Disease Prevalence
- 7.8.3.3. Regulatory Framework
- 7.8.3.4. Reimbursement Framework
- 7.8.3.5. Saudi Arabia Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Type Disease Prevalence
- 7.8.4.3. Regulatory Framework
- 7.8.4.4. Reimbursement Framework
- 7.8.4.5. UAE Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Type Disease Prevalence
- 7.8.5.3. Regulatory Framework
- 7.8.5.4. Reimbursement Framework
- 7.8.5.5. Kuwait Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- Chapter 8. Competitive Landscape
- 8.1. Participant Overview
- 8.2. Company Market Position Analysis
- 8.3. Company Categorization
- 8.4. Strategy Mapping
- 8.5. Company Profiles/Listing
- 8.5.1. Amgen Inc
- 8.5.1.1. Overview
- 8.5.1.2. Financial Performance
- 8.5.1.3. Product Benchmarking
- 8.5.1.4. Strategic Initiatives
- 8.5.2. F Hoffman-La Roche Ltd.
- 8.5.2.1. Overview
- 8.5.2.2. Financial Performance
- 8.5.2.3. Product Benchmarking
- 8.5.2.4. Strategic Initiatives
- 8.5.3. Sandoz International GmbH
- 8.5.3.1. Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Product Benchmarking
- 8.5.3.4. Strategic Initiatives
- 8.5.4. Dr. Reddy’s Laboratories Ltd.
- 8.5.4.1. Overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Product Benchmarking
- 8.5.4.4. Strategic Initiatives
- 8.5.5. Teva Pharmaceutical Industries Ltd.
- 8.5.5.1. Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Product Benchmarking
- 8.5.5.4. Strategic Initiatives
- 8.5.6. Pfizer Inc.
- 8.5.6.1. Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Product Benchmarking
- 8.5.6.4. Strategic Initiatives
- 8.5.7. Samsung Biopis
- 8.5.7.1. Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Product Benchmarking
- 8.5.7.4. Strategic Initiatives
- 8.5.8. Biocon
- 8.5.8.1. Overview
- 8.5.8.2. Financial Performance
- 8.5.8.3. Product Benchmarking
- 8.5.8.4. Strategic Initiatives
- 8.5.9. Viatris Inc.
- 8.5.9.1. Overview
- 8.5.9.2. Financial Performance
- 8.5.9.3. Product Benchmarking
- 8.5.9.4. Strategic Initiatives
- 8.5.10. Celltrion Healthcare Co., Ltd.
- 8.5.10.1. Overview
- 8.5.10.2. Financial Performance
- 8.5.10.3. Product Benchmarking
- 8.5.10.4. Strategic Initiatives
- 8.5.11. AbbVie Inc.
- 8.5.11.1. Overview
- 8.5.11.2. Financial Performance
- 8.5.11.3. Product Benchmarking
- 8.5.11.4. Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
